Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:41:17 17/05/2024 pm IST			5-day change	1st Jan Change
904.5 ^DKK	-0.92%		-0.57%	+29.59%

16/05	Health Care Flat as Momentum Wanes -- Health Care Roundup	DJ
16/05	Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark	MT

NOVO NORDISK : Gets a Buy rating from Barclays

May 02, 2024 at 05:33 pm IST

In a research note published by Emily Field, Barclays advises its customers to buy the stock. The target price remains set at DKK 1050.

Latest news about Novo Nordisk A/S

Health Care Flat as Momentum Wanes -- Health Care Roundup	17/05	DJ
Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark	16/05	MT
Novo Nordisk Building Under Construction at Manufacturing Hub in Denmark Hit by Fire	16/05	MT
India's Biocon posts Q4 profit fall as higher raw material costs bite	16/05	RE
NOVO NORDISK: FIRE AT KALUNDBORG SITE HAS NO IMPACT ON EXISTING…	16/05	RE
Novo Nordisk building site hit by fire, Danish TV2 reports	16/05	RE
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial -- Update	16/05	DJ
Roche Gains as Weight-loss Injection Shows Potential in Early-stage Study	16/05	MT
Roche shares gain on obesity drug results from early-stage trial	16/05	RE
US Senate Committee Warns of Potential Healthcare Bankruptcy Due to Novo Nordisk's Wegovy	16/05	MT
Health Care Up on Momentum -- Health Care Roundup	16/05	DJ
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	16/05	MT
Sector Update: Health Care	16/05	MT
Novo Nordisk Weigh-Loss Drugs Could Bankrupt US Health Care, Senate Committee Report Says	16/05	MT
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down	15/05	RE
Novo Nordisk Owner to Buy Controlling Stake in Single Use Support	15/05	MT
NOVO NORDISK : UBS sticks Neutral	15/05	ZD
Health Care Up on Improved Risk Appetite -- Health Care Roundup	15/05	DJ
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs	15/05	RE
Novo Nordisk's Wegovy Reduces Cardiac Events, Sustains Weight Loss, New Analysis Shows	14/05	MT
Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal	14/05	MT
NOVO NORDISK : JP Morgan reaffirms its Buy rating	14/05	ZD
NOVO NORDISK : UBS reaffirms its Neutral rating	14/05	ZD
Stifel Lifts Novo Nordisk PT, Keeps Buy Recommendation	14/05	MT
Novo Nordisk Plans First Bond Sale in Two Years	14/05	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 10:06 pm IST

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 09:39 pm IST

Novo Nordisk doesn't disappoint

January 31, 2024 at 09:18 pm IST

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

912.9 DKK

Average target price

909.2 DKK

Spread / Average Target

-0.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+29.59%	593B
ELI LILLY AND COMPANY	+32.36%	694B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.40%	239B
NOVARTIS AG	+10.37%	209B
ROCHE HOLDING AG	-3.31%	209B
AMGEN INC.	+9.27%	169B
PFIZER, INC.	+0.45%	164B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Gets a Buy rating from Barclays

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals